Regulatory Requirement for Pharmaceutical Marketing in USA, EU and GCC: A Comparison
DOI:
https://doi.org/10.37591/rrjodfdp.v1i3.318Abstract
The Gulf Cooperation Council (GCC) pharmaceutical are known to be a semi-regulated market when compared with European Union (EU) and Unites States of America (USA) drug regulatory market. Product registration in GCC was challenging task in comparison to EU and USA due to lack of proper harmonised guidelines and diversity in registration procedure. The six GCC member states namely Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and United Arab Emirates have established a good regulatory guideline of their own, for drug marketing. Need for establishment of well-regulated guidelines is to ensure quality, safety and efficacy of drugs. The regulatory guidelines of EU and USA are standard for other regulatory agencies worldwide, and also to semi-regulated countries of GCC. This paper mainly focuses the various aspects of registration procedures, scope and time lines for the registration in USA, EU and GCC. A comparison between regulatory procedures of GCC with USA and EU countries will give us complete view on GCC countries being well regulated and emerging pharmaceutical market.
Keywords: United States Food and Drug Administration (USFDA), Gulf Cooperation Council (GCC), European Medicines Agency (EMA)
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |